Goldman Sachs Alzheimer’s Disease Day — Infrastructure considerations: Outlook for blood-based testing

Oct 3

Below is a recording of the session titled: Infrastructure considerations: Outlook for blood-based testing as part of the Goldman Sachs Alzheimer’s Disease Day, held on October 3, 2023 in New York City. Dr. Joel Braunstein, CEO of C₂N Diagnostics, provides remarks on the outlook for blood-based testing for Alzheimer’s disease. Matt Sykes, Vice President of Goldman Sachs serves as moderator.

Unlock the Session below.

Name

First Name

Last Name

Company/Organization

Zip code

I’d like to learn more about the Precivity™ tests.

Yes

Joni Henderson

Goldman Sachs Alzheimer’s Disease Day — Infrastructure considerations: Outlook for blood-based testing

Clinical Use of Blood Biomarkers in the Era of Disease Modifying Treatments for Early Symptomatic Alzheimer’s Disease

Diagnostic Tools & The New Blood Test

C₂N Diagnostics